Corrigendum to 'Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study': [ESMO Open Volume 6, Issue 4, August 2021, 100191]
对“吉非替尼诱导治疗后进行放化疗治疗 EGFR 突变局部晚期非小细胞肺癌：LOGIK0902/OLCSG0905 II 期研究”的更正：[ESMO Open 第 6 卷，第 4 期，2021 年 8 月，100191]
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100532
Hotta, K; Saeki, S; Yamaguchi, M; Harada, D; Bessho, A; Tanaka, K; Inoue, K; Gemba, K; Shiojiri, M; Kato, Y; Ninomiya, T; Kubo, T; Kishimoto, J; Shioyama, Y; Katsui, K; Sasaki, J; Kiura, K; Sugio, K
